Ocugen (OCGN) Stock Overview
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OCGN Community Fair Values
Create NarrativeSee what 87 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ocugen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$2.73 |
| 52 Week Low | US$0.96 |
| Beta | 2.2 |
| 1 Month Change | -12.93% |
| 3 Month Change | -13.51% |
| 1 Year Change | 28.21% |
| 3 Year Change | 155.54% |
| 5 Year Change | -82.75% |
| Change since IPO | -55.09% |
Recent News & Updates
Narrative Update • Aug 02
OCGN: Upcoming Gene Therapy Trials And RMAT Pathway Could Re Rate Shares
Ocugen's updated analyst price target has shifted modestly to $11 from $12, with analysts pointing to recent discussions on upcoming clinical milestones and trial preparations as the key reasons for refining their models. Analyst Commentary Recent commentary on Ocugen highlights a mix of interest in the clinical pipeline and caution around how that pipeline translates into long term value.
Narrative Update • Jul 07
OCGN: Upcoming Retinal Trial Readouts Will Shape Future Upside Potential
Analysts raised their fair value estimate for Ocugen to about $20.62 from $15.00, citing updated assumptions for revenue potential, profitability, and a lower expected future P/E multiple based on recent clinical and regulatory progress discussed in recent research. Analyst Commentary Recent Street research on Ocugen shows a mix of optimism around the pipeline and caution around timing and execution, which together help explain the latest fair value revisions.Recent updates
Narrative Update • Aug 02
OCGN: Upcoming Gene Therapy Trials And RMAT Pathway Could Re Rate Shares
Ocugen's updated analyst price target has shifted modestly to $11 from $12, with analysts pointing to recent discussions on upcoming clinical milestones and trial preparations as the key reasons for refining their models. Analyst Commentary Recent commentary on Ocugen highlights a mix of interest in the clinical pipeline and caution around how that pipeline translates into long term value.Narrative Update • Jul 07
OCGN: Upcoming Retinal Trial Readouts Will Shape Future Upside Potential
Analysts raised their fair value estimate for Ocugen to about $20.62 from $15.00, citing updated assumptions for revenue potential, profitability, and a lower expected future P/E multiple based on recent clinical and regulatory progress discussed in recent research. Analyst Commentary Recent Street research on Ocugen shows a mix of optimism around the pipeline and caution around timing and execution, which together help explain the latest fair value revisions.
Narrative Update • Jun 23
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.Narrative Update • Jun 05
OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.Narrative Update • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.Narrative Update • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.Narrative Update • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.Narrative Update • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Seeking Alpha • Mar 09
Ocugen: Downgrading After OCU410 Data Release
Summary Ocugen (OCGN) is downgraded from 'Buy' to 'Hold' due to concerns over OCU410's dose response in geographic atrophy. Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final ArMaDa data [March 2026], OCU410ST interim [Q3 2026] and topline [Q2 2027], and OCU400 RP topline [Q1 2027]. Company's cash runway extends to Q4 2026 [potentially Q2 2027 with warrant exercise], but quarterly burn and multiple late-stage trial risks remain. Read the full article on Seeking AlphaNarrative Update • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.Narrative Update • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.Narrative Update • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.Narrative Update • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.Narrative Update • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.Narrative Update • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.Narrative Update • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.Narrative Update • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Narrative Update • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Narrative Update • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
New Narrative • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Shareholder Returns
| OCGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.1% | 6.3% | 4.2% |
| 1Y | 28.2% | 40.9% | 20.6% |
Return vs Industry: OCGN underperformed the US Biotechs industry which returned 40.9% over the past year.
Return vs Market: OCGN exceeded the US Market which returned 20.6% over the past year.
Price Volatility
| OCGN volatility | |
|---|---|
| OCGN Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OCGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OCGN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 116 | Shankar Musunuri | www.ocugen.com |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
Ocugen, Inc. Fundamentals Summary
| OCGN fundamental statistics | |
|---|---|
| Market cap | US$433.31m |
| Earnings (TTM) | -US$71.67m |
| Revenue (TTM) | US$4.47m |
97.0x
P/S Ratio-6.0x
P/E RatioIs OCGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCGN income statement (TTM) | |
|---|---|
| Revenue | US$4.47m |
| Cost of Revenue | US$41.48m |
| Gross Profit | -US$37.01m |
| Other Expenses | US$34.66m |
| Earnings | -US$71.67m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | -828.91% |
| Net Profit Margin | -1,605.22% |
| Debt/Equity Ratio | 502.9% |
How did OCGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 08:59 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ocugen, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |